Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD6-CAR Tregs in cGVHD
NCT05993611Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Feb 2024
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD6-CAR Tregs in chronic graft-versus-host disease (cGVHD), sponsored by City of Hope. Primary endpoints: Dose-limiting toxicity at 28 days, Feasibility as the ability to met at least 80% of the required cell dose at 28 days and 1 more. Started Feb 2024; status: suspended.
02
Drugs
CD6-CAR Tregs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05993611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993611.